Acurx Pharmaceuticals Implements Strategic Reverse Stock Split
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) has announced an executive decision regarding its stock structure. The company is set to begin trading its common stock on a post-split adjusted basis. This adjustment comes as part of a strategic move to bolster its market position and stock price.
The Reverse Stock Split Explained
The board of directors has sanctioned a 1-for-20 reverse stock split, a decision overwhelmingly supported by stockholders during their annual meeting. This measure is designed to improve the per share price of Acurx's stock to meet the compliance standards set by The Nasdaq Capital Market.
Understanding the Mechanics of the Split
In practical terms, the reverse stock split will convert every twenty existing shares into a single share of common stock. This action will not create fractional shares; instead, stockholders who would have received a fraction of a share will obtain a cash payment based on the adjusted value of their fractional interest prior to the reverse split.
Impact on Share Count and Trading
As of late July, Acurx had about 30.76 million shares outstanding. Following the implementation of the reverse split, this number will drop significantly to around 1.54 million shares. Importantly, while the number of outstanding shares will decrease, the total authorized number of shares will remain unchanged.
How Stockholders Will Be Affected
This corporate action is particularly noteworthy for stockholders holding shares in different formats. For those with electronic positions, there’s no need for any additional action as their holdings will be automatically adjusted. Conversely, stockholders with physical certificates will receive detailed instructions from the company’s transfer agent for the exchange of their certificates.
Acurx's Commitment to Innovative Antibiotics
Acurx Pharmaceuticals positions itself as a pioneer in biopharmaceutical developments, specifically targeting challenging bacterial infections with its innovative drug candidates. The company's strategic focus is to produce antibiotics that are specifically effective against Gram-positive bacteria, which pose significant treatment difficulties.
Pipeline Products and Future Prospects
Among Acurx's leading candidates is ibezapolstat, intended for treating C. difficile infections. The substance is poised for Phase 3 clinical trials, with preparation efforts underway for international studies. This critical stage is dependent on securing necessary financing but signifies an exciting future for the company's product pipeline.
Broader R&D Initiatives
In addition to ibezapolstat, Acurx is aggressively developing other candidates targeted at infections like MRSA and VRE. Their pipeline highlights a robust approach to antibiotic development, addressing various serious health threats and reinforcing the company’s commitment to public health.
Contact Information
For further inquiries, interested parties can reach out to David P. Luci, President & Chief Executive Officer of Acurx Pharmaceuticals, Inc., at 917-533-1469. The company remains keen on facilitating communication regarding its innovative projects and corporate changes.
Frequently Asked Questions
What is a reverse stock split?
A reverse stock split is a corporate action where a company reduces the number of its outstanding shares, increasing the share price proportionately.
Why did Acurx conduct a reverse stock split?
The primary goal is to boost the per-share trading price to comply with Nasdaq's minimum listing requirements, which is crucial for maintaining its market presence.
How will I be affected if I own Acurx shares?
If you own shares electronically through a broker, your holdings will automatically adjust. Physical stockholders will receive instructions for converting their shares.
What does this mean for Acurx's future?
This strategic move is aimed at stabilizing the stock price and supporting ongoing developments in their antibiotic pipeline, ultimately facilitating growth and innovation.
Who can I contact for more information?
For more details, contact David P. Luci at Acurx Pharmaceuticals through the given phone number.
